Aranesp Bi-Weekly Dose Can Substitute For Once-Weekly Procrit - Labeling
Amgen's novel erythropoiesis stimulating protein Aranesp is labeled for administration once every two weeks when it is replacing a once-weekly dose of Johnson & Johnson's Procrit (epoetin alfa).
You may also be interested in...
Amgen is launching the anemia agent Aranesp at a price falling in the middle of the range for Johnson & Johnson's erythropoietin brand Procrit.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials